1 reports of this reaction
6.3% of all FERRUM PHOSPHORICUM reports
#11 most reported adverse reaction
SICKLE CELL ANAEMIA is the #11 most commonly reported adverse reaction for FERRUM PHOSPHORICUM, manufactured by Energique, Inc.. There are 1 FDA adverse event reports linking FERRUM PHOSPHORICUM to SICKLE CELL ANAEMIA. This represents approximately 6.3% of all 16 adverse event reports for this drug.
Patients taking FERRUM PHOSPHORICUM who experience sickle cell anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SICKLE CELL ANAEMIA is moderately reported among FERRUM PHOSPHORICUM users, representing a notable but not dominant share of adverse events.
In addition to sickle cell anaemia, the following adverse reactions have been reported for FERRUM PHOSPHORICUM:
SICKLE CELL ANAEMIA has been reported as an adverse event in 1 FDA reports for FERRUM PHOSPHORICUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SICKLE CELL ANAEMIA accounts for approximately 6.3% of all adverse event reports for FERRUM PHOSPHORICUM, making it a notable side effect.
If you experience sickle cell anaemia while taking FERRUM PHOSPHORICUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.